281 related articles for article (PubMed ID: 36661102)
1. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
2. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Ozaki K; Hatakeyama S; Narita S; Hata K; Yanagisawa T; Tanaka T; Togashi K; Hamaya T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Kimura T; Habuchi T; Ohyama C
World J Urol; 2023 Jan; 41(1):67-75. PubMed ID: 36520204
[TBL] [Abstract][Full Text] [Related]
4. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
5. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Habuchi T
Int J Clin Oncol; 2022 Sep; 27(9):1477-1486. PubMed ID: 35748967
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G
Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O; Carthon B; Nazha B; Bilen MA
Oncologist; 2021 Nov; 26(11):956-964. PubMed ID: 34096667
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
11. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
[TBL] [Abstract][Full Text] [Related]
12. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Tsaur I; Heidegger I; Bektic J; Kafka M; van den Bergh RCN; Hunting JCB; Thomas A; Brandt MP; Höfner T; Debedde E; Thibault C; Ermacora P; Zattoni F; Foti S; Kretschmer A; Ploussard G; Rodler S; von Amsberg G; Tilki D; Surcel C; Rosenzweig B; Gadot M; Gandaglia G; Dotzauer R;
Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489
[TBL] [Abstract][Full Text] [Related]
13. Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.
Briones J; Khan M; Sidhu AK; Zhang L; Smoragiewicz M; Emmenegger U
Front Oncol; 2021; 11():658331. PubMed ID: 34026638
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
[TBL] [Abstract][Full Text] [Related]
16. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
19. Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.
Muto Y; Narita S; Hatakeyama S; Maita S; Chiba S; Kubo K; Aoyama Y; Ito R; Takahashi Y; Takahashi S; Nakamura K; Honma N; Sato H; Koizumi A; Igarashi R; Okane K; Ishida T; Horikawa Y; Kumazawa T; Akihama S; Shimoda J; Suzuki T; Ohyama C; Habuchi T
Med Oncol; 2021 Mar; 38(4):37. PubMed ID: 33713196
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
